Selective inhibitors of cyclooxygenase-2 delay the activation of nuclear factor κB and attenuate the expression of inflammatory genes in murine macrophages treated with lipopolysaccharide

Molecular Pharmacology

Volumn 63, Issue 3, 2003, Pages 671-677

  Callejas, Nuria A ^a   Fernández Martínez, Amalia ^a   Castrillo, Antonio ^a   Boscá, Lisardo ^a   Martín Sanz, Paloma ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUOROETHYL N,N DIMETHYLCARBAMATE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUORINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NITRIC OXIDE SYNTHASE; PROTEIN P44; ROFECOXIB; SALICYLIC ACID; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; INFLAMMATION; INHIBITION KINETICS; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENZYME ACTIVATION; GENE EXPRESSION; I-KAPPA B KINASE; ISOENZYMES; LACTONES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; SULFONES;

EID: 0037334544     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.3.671     Document Type: Article

References (43)

1. Baatar D, Jones MK, Pai R, Kawanaka H, Szabo IL, Moon WS, Kitano S, and Tarnawski AS (2002) Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered C-met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation. Am J Pathol 160:963-972.
2. Callejas NA, Bosca L, Williams CS, DuBois RN, and Martin-Sanz P (2000) Regulation of cyclooxygenase-2 expression in hepatocytes by CCAAT-enhancer binding proteins. Gastroenterology 119:493-501.
3. Callejas NA, Casado M, Bosca L, and Martin-Sanz P (2002) Absence of nuclear factor κB inhibition by NSAIDs in hepatocytes. Hepatology 35:341-348.
4. Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L, and Martin-Sanz P (2001) Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33:860-867.
5. 2 in activated murine macrophages. Mol Cell Biol 20:1692-1698.
6. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560.
7. Depre M, Ehrich E, Van Hecken A, De L, I, Dallob A, Wong P, Porras A, Gertz BJ, and De Schepper PJ (2000) Pharmacokinetics, COX-2 specificity and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 56:167-174.
8. DeWitt DL (1991) Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1083:121-134.
9. DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55:625-631.
10. Diaz-Guerra MJM, Castrillo A, Martin-Sanz P, and Bosca L (1999) Negative regulation by protein tyrosine phosphatase of IFN-γ-dependent expression of inducible nitric oxide synthase. J Immunol 162:6776-6783.
11. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, and Karin M (1997) A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature (Lond) 388:548-554.
12. Feng L, Xia Y, Garcia GE, Hwang D, and Wilson CB (1995) Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-α and lipopolysaccharide. J Clin Investig 95:1669-1675.
13. Ghosh S, May MJ, and Kopp EB (1998) NF-κB and Re1 proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
14. Gupta RA and DuBois RN (2000) Combinations for cancer prevention. Nat Med 6:974-975.
15. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, and Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418-1423.
16. Karin M (1999) The beginning of the end: IκB kinase (IKK) and NF-κB activation. J Biol Chem 274:27339-27342.
17. Kim TH, Mars WM, Stolz DB, and Michalopoulos GK (2000) Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology 31:75-82.
18. Langenbach R, Loftin CD, Lee C, and Tiano H (1999) Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann NY Acad Sci 889:52-61.
19. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al. (1999) Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 354:1932-1939.
20. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, and Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228-3232.
21. May MJ and Ghosh S (1998) Signal transduction through NF-κB. Immunol Today 19:80-88.
22. McCarthy DM (1999) Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 107:37S-46S.
23. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Bräutigam L, Grosch S, and Geisslinger G (2001) Celecoxib loses its antiinflammatory efficacy at high doses through activation of NF-κB. FASEB J 15: 1622-1624.
24. Pilbeam CC, Kawaguchi H, Hakeda Y, Voznesensky O, Alander CB, and Raisz LG (1993) Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 Cells. J Biol Chem 268:25643-25649.
25. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, and Weissmann G (1998) Modes of action of aspirin-like drugs: salicylates inhibit Erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 95:14540-14545.
26. Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, and Nagasue N (2000) Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 60:2085-2089.
27. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, et al. (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121:105-117.
28. Saccani S, Pantano S, and Natoli G (2001) Two waves of nuclear factor κB recruitment to target promoters. J Exp Med 193:1351-1359.
29. Schwenger P, Alpert D, Skolnik EY, and Vilcek J (1998) Activation of P38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκB alpha phosphorylation and degradation. Mol Cell Biol 18:78-84.
30. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, and Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017.
31. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, and Geis GS (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591-1602.
32. Smith WL, Garavito RM, and DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157-33160.
33. Tegeder I, Pfeilschifter J, and Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072.
34. Terenzi F, Diaz-Guerra MJ, Casado M, Hortelano S, Leoni S, and Bosca L (1995) Bacterial lipopeptides induce nitric oxide synthase and promote apoptosis through nitric oxide-independent pathways in rat macrophages. J Biol Chem 270:6017-6021.
35. Thanos D and Maniatis T (1995) NF-KB: a lesson in family values. Cell 80:529-532.
36. Thun MJ, Namboodiri MM, and Heath CWJ (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596.
37. Tsujii M, Kawano S, and DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340.
38. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, and DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716.
39. Velasco M, Diaz-Guerra MJ, Martin-Sanz P, Alvarez A, and Bosca L (1997) Rapid up-regulation of IκBβ and abrogation of NF-KB activity in peritoneal macrophages stimulated with lipopolysaccharide. J Biol Chem 272:23025-23030.
40. Williams CS and DuBois RN (1996) Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270:G393-G400.
41. Williams CS, Mann M, and DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer and development. Oncogene 18:7908-7916.
42. Yin MJ, Yamamoto Y, and Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature (Lond) 396:77-80.
43. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, and Karin M (1997) The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-KB activation. Cell 91:243-252.